PA tablets: investigational compounds combining aspirin and omeprazole for cardioprotection.

Journal Article (Review)

For most patients with prior cardiovascular events, preventing future secondary cardiovascular events requires life-long persistence with antiplatelet therapy. PA tablets (P: proton pump inhibitors; A: aspirin) are investigational compounds that were developed to provide the cardioprotective benefits of aspirin with the upper gastrointestinal protection of a proton pump inhibitor (e.g., omeprazole). The tablets are film-coated, coordinated-release tablets for oral administration that contain 40 mg immediate-release omeprazole and either 81 or 325 mg delayed-release aspirin. The goals of the clinical development program were to demonstrate the following: improved gastrointestinal safety of PA relative to enteric-coated aspirin alone; bioequivalence and comparative bioavailability between the PA compounds and currently marketed enteric-coated aspirin; and long-term safety. Two clinical pharmacology studies were also conducted to study the potential for interaction between PA32540 and clopidogrel.

Full Text

Duke Authors

Cited Authors

  • Bliden, KP; Brener, M; Gesheff, MG; Franzese, CJ; Tabrizchi, A; Tantry, U; Gurbel, PA

Published Date

  • November 2013

Published In

Volume / Issue

  • 9 / 6

Start / End Page

  • 785 - 797

PubMed ID

  • 24180537

Electronic International Standard Serial Number (EISSN)

  • 1744-8298

Digital Object Identifier (DOI)

  • 10.2217/fca.13.67

Language

  • eng

Conference Location

  • England